1. Introduction {#sec1-jcm-09-02089}
===============

Heart failure (HF) is a clinical syndrome caused by a structural or functional heart abnormality leading to a reduction of cardiac output or an increase in intracardiac pressure. Characterization of HF is usually based on the ejection fraction (EF): preserved (≥50%), mid-range (40--49%), or reduced (\<40%) \[[@B1-jcm-09-02089]\].

Although HF is increasingly treatable and preventable, it remains one of the main causes of morbidity, mortality, and high healthcare costs. Incidence and prevalence of HF increase with population aging. Greater prevalence is related to increased survival, due to successful HF treatment, and higher incidence is related to the increasing population prevalence of atrial fibrillation, hypertension, obesity, and diabetes \[[@B1-jcm-09-02089],[@B2-jcm-09-02089],[@B3-jcm-09-02089]\]. In 2018, HF caused 19,142 deaths in Spain \[[@B4-jcm-09-02089]\]. While the morbidity and mortality of patients with reduced EF (40--60% of HF patients) \[[@B5-jcm-09-02089],[@B6-jcm-09-02089],[@B7-jcm-09-02089]\] have decreased, thanks to improved clinical management in recent decades \[[@B8-jcm-09-02089]\], the average total cost per patient with HF in Spain was €12,995--18,220 in 2010, with the largest cost item (59.1--69.8%) being non-professional care \[[@B9-jcm-09-02089]\]. The total HF-patient healthcare expenditure as a percentage of the annual healthcare budget is 1.5% in all of Spain and 7.1% in Catalonia, with the highest cost in both cases related to hospitalizations \[[@B10-jcm-09-02089],[@B11-jcm-09-02089]\].

Prevalence, clinical characteristics, and prognosis of HF differ according to EF category. Time series based on data from hospitalized patients suggest a more pronounced decrease in HF incidence and show higher all-cause mortality but fewer comorbidities in patients with reduced EF, compared to preserved EF \[[@B1-jcm-09-02089]\].

Comorbidities are a key component in the management of patients with HF, as treatments for accompanying pathologies can worsen HF prognosis \[[@B1-jcm-09-02089]\]. Two of the most common comorbidities are diabetes (20--40%) and chronic kidney disease (10--30%) \[[@B12-jcm-09-02089],[@B13-jcm-09-02089]\]. Both are associated with more hospitalizations and higher mortality in HF patients \[[@B14-jcm-09-02089]\].

The good quality of HF mortality data in Spain contrasts with the lesser-known prevalence of the disease. Several studies have analysed the population prevalence of HF in Spain, providing estimations that vary considerably (2.7--6.8%) for the population older than 44 years \[[@B14-jcm-09-02089],[@B15-jcm-09-02089],[@B16-jcm-09-02089]\]. Most of these figures exceed the estimations in adult populations of Europe (1--2%) \[[@B1-jcm-09-02089],[@B17-jcm-09-02089],[@B18-jcm-09-02089]\] and North America (2.2--2.4%) \[[@B2-jcm-09-02089],[@B19-jcm-09-02089]\]. Moreover, no data are available on the prevalence of HF with reduced EF and comorbidities, the patient profile associated with the highest HF mortality.

Although advances in HF treatment have significantly reduced mortality risk in clinical trials, particularly in patients with reduced EF, the real-life impact of improved treatment has been more modest \[[@B20-jcm-09-02089]\]. One new option is dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor with solid clinical evidence in patients with type 2 diabetes mellitus (T2D) that also markedly reduces hospitalization for HF \[[@B21-jcm-09-02089]\]. Dapagliflozin has reduced cardiovascular mortality and hospitalization for HF, compared to a placebo, as an additional treatment in patients with chronic HF and reduced EF, with and without T2D \[[@B22-jcm-09-02089]\]. In view of these promising results, it would be useful to determine the target population for this new treatment indication, based on the criteria used in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study \[[@B22-jcm-09-02089]\]. Spain did not participate in the DAPA-HF study; therefore, there is a great interest to know the impact of the DAPA-HF study criteria in the Spanish population.

The aim of this study was to estimate the population in Spain, stratified by its autonomous communities, that meets the DAPA-HF criteria for dapagliflozin indication: HF and reduced EF (≤40%), functional class II--IV of the New York Heart Association (NYHA), and glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m², all with and without T2D.

2. Materials and Methods {#sec2-jcm-09-02089}
========================

2.1. Study Design and Population {#sec2dot1-jcm-09-02089}
--------------------------------

To determine the number of patients with HF with reduced EF, in NYHA functional class II--IV, and with normal or moderate kidney function (≥ 30 mL/min/1.73 m²), we carried out a systematic literature search in PubMed of English or Spanish cross-sectional, cohort, population-based, or other epidemiological studies. To this end, we selected articles that contained the terms ''heart failure'' in the title; ''prevalence'' or ''burden'' in the title or abstract; ''ejection fraction'', ''systole'', or ''systolic'' in the title or abstract; and ''general population'' or ''healthy'' in the title or abstract (search date: September 1, 2017). This systematic search was updated on April 15, 2020, and supplemented with articles provided by experts \[[@B12-jcm-09-02089],[@B13-jcm-09-02089],[@B20-jcm-09-02089],[@B21-jcm-09-02089],[@B22-jcm-09-02089],[@B23-jcm-09-02089],[@B24-jcm-09-02089]\].

Patients' eligibility criteria for the population candidates for dapagliflozin treatment are summarized in [Table 1](#jcm-09-02089-t001){ref-type="table"}. Full details are provided in the design paper \[[@B25-jcm-09-02089]\].

2.2. Estimation of Population Prevalence and Number of Patients with Heart Failure in Spain {#sec2dot2-jcm-09-02089}
-------------------------------------------------------------------------------------------

Our analysis applied the prevalence of HF reported for individuals older than 44 years in the largest and most recent representative population study \[[@B14-jcm-09-02089]\] to the entire Spanish population and to each autonomous community's population, according to the 2019 Spanish National Statistics Institute data \[[@B26-jcm-09-02089]\].

2.3. Estimation of Ejection Fraction ≤ 40% and New York Heart Association Functional Class II--IV Prevalence in the Heart Failure Population in Spain {#sec2dot3-jcm-09-02089}
-----------------------------------------------------------------------------------------------------------------------------------------------------

The proportion of HF patients with EF ≤ 40% and NYHA functional class II--IV was determined according to the average percentages observed in the most recent Spanish registries of patients with chronic HF \[[@B6-jcm-09-02089],[@B7-jcm-09-02089],[@B27-jcm-09-02089],[@B28-jcm-09-02089],[@B29-jcm-09-02089]\]. The study designs, in reverse chronological order, are summarized as follows:

Prospective cohort studies:RICA (National Registry for Heart Failure), carried out in internal medicine units in 52 public and private hospitals \[[@B27-jcm-09-02089]\];REDINSCOR (Spanish Network for Heart Failure), carried out in HF units in 18 hospitals \[[@B27-jcm-09-02089]\];BADAPIC (Database of Patients with Heart Failure), involving 62 centres with specific HF units or clinics \[[@B6-jcm-09-02089]\];

Cross-sectional studies:INCA (Heart Failure Study), involving 415 primary care physicians and 93 cardiologists \[[@B7-jcm-09-02089]\];EPISERVE (Heart Failure in Outpatients), carried out by 181 primary care physicians, 172 cardiologists, and 154 internal medicine physicians \[[@B28-jcm-09-02089]\];GALICAP (Galician Study of Heart Failure in Primary Care), involving 149 primary care physicians distributed in eight areas of Galicia \[[@B29-jcm-09-02089]\].

2.4. Estimation of Glomerular Filtration Rate ≥ 30 mL/min/1.73 m² Prevalence in the Heart Failure Population in Spain {#sec2dot4-jcm-09-02089}
---------------------------------------------------------------------------------------------------------------------

The proportion of patients with GFR ≥ 30 mL/min/1.73 m² was estimated from the most generalizable data, obtained from patients with chronic HF in 28 Spanish hospitals included in the European Society of Cardiology (ESC) Heart Failure Long-Term Registry \[[@B23-jcm-09-02089]\]. The prevalence of GFR ≥ 30 mL/min/1.73 m² was applied to the estimated HF population with EF ≤ 40% and with NYHA functional class II--IV (obtained in [Section 2.3](#sec2dot3-jcm-09-02089){ref-type="sec"}).

A sensitivity analysis with the total REDINSCOR prevalence of EF, NYHA functional class II--IV, and GFR ≥ 30 mL/min/1.73 m² was done to determine the reliability of our estimates ([Tables S1--S3](#app1-jcm-09-02089){ref-type="app"}).

2.5. Estimation of Type 2 Diabetes Mellitus Prevalence in the Heart Failure Population in Spain {#sec2dot5-jcm-09-02089}
-----------------------------------------------------------------------------------------------

Finally, the prevalence of patients with and without T2D was obtained from a specific analysis of a chronic HF cohort provided by REDINSCOR investigators. The cohort characteristics have been described previously \[[@B27-jcm-09-02089],[@B30-jcm-09-02089]\]. We calculated the prevalence of patients with and without diabetes who met the criteria for HF with EF ≤ 40%, NYHA functional class II--IV, and GFR ≥ 30 mL/min/1.73 m² ([Tables S1 and S2](#app1-jcm-09-02089){ref-type="app"}).

2.6. Statistical Analysis {#sec2dot6-jcm-09-02089}
-------------------------

The arithmetic means of reduced EF and NYHA functional class II--IV estimations were obtained. The 95% confidence interval (CI) for the described estimations were obtained by assuming a Poisson distribution of patient counts. Analysis was carried out using R software, version 4.0.0.

3. Results {#sec3-jcm-09-02089}
==========

3.1. Estimation of Population Prevalence and Number of Patients with Heart Failure in Spain {#sec3dot1-jcm-09-02089}
-------------------------------------------------------------------------------------------

[Table 2](#jcm-09-02089-t002){ref-type="table"} describes the prevalence of HF in Spain and in Europe, as reported in the largest, most recent, and most representative population-based candidate studies. The 2012 study by Farré et al. \[[@B14-jcm-09-02089]\] was considered the most appropriate for estimating prevalence in Spain, since it included a representative population of more than 88,000 people and the results closely resembled those of similar studies in Europe. Applying the prevalence of specific ages used by Farré et al. \[[@B14-jcm-09-02089]\] to current Spanish population in the same age groups yielded a prevalence of approximately 2.6% in the group older than 44 years, or 594,684 (95% CI: 593,175--596,196) patients with HF.

3.2. Estimation of Ejection Fraction ≤ 40% and New York Heart Association Functional Class II--IV Prevalence in the Heart Failure Population in Spain {#sec3dot2-jcm-09-02089}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Characteristics of patients with HF included in the selected Spanish studies are shown in [Table 3](#jcm-09-02089-t003){ref-type="table"}. The average proportion of HF patients with EF ≤ 40% was 52.4%, of which 84.0% had NYHA functional class II--IV. Applying these percentages to the estimated number of patients with HF in Spain, 311,614 (95% CI: 310,522--312,709) patients would have EF ≤ 40%, and 261,756 (95% CI: 260,755--262,760) patients would also have NYHA functional class II--IV.

The Spanish population and the number of patients with HF, by age group and by autonomous community, are shown in [Table 4](#jcm-09-02089-t004){ref-type="table"}. In [Table 5](#jcm-09-02089-t005){ref-type="table"}, these data are disaggregated by EF ≤ 40%, and by the combination of EF ≤ 40% and NYHA functional class II--IV.

3.3. Estimation of Glomerular Filtration Rate ≥ 30 mL/min/1.73 m² Prevalence in the Heart Failure Population in Spain {#sec3dot3-jcm-09-02089}
---------------------------------------------------------------------------------------------------------------------

According to the prevalence of chronic HF patients with GFR ≥ 30 mL/min/1.73 m² described by Crespo-Lerio \[[@B23-jcm-09-02089]\], we estimated the number of HF patients with the combination of EF ≤ 40%, NYHA functional class II--IV, and GFR ≥ 30 mL/min/1.73 m² ([Table 6](#jcm-09-02089-t006){ref-type="table"}). In Spain, an estimated 245,789 (95% CI: 244,819--246,762) patients would have these characteristics.

A sensitivity analysis with REDINSCOR estimates ([Table S3](#app1-jcm-09-02089){ref-type="app"}), however, showed that the estimated number of patients who met the clinical characteristics of participants in the DAPA-HF trial were 353,658 (95% CI: 352,494--354,825).

3.4. Estimation of Type 2 Diabetes Mellitus Prevalence in the Heart Failure Population in Spain {#sec3dot4-jcm-09-02089}
-----------------------------------------------------------------------------------------------

The number of HF patients with EF ≤ 40%, NYHA functional class II--IV, and GFR ≥ 30 mL/min/1.73 m², with and without T2D, are shown in [Table 7](#jcm-09-02089-t007){ref-type="table"} by age group and autonomous community. With these prevalence data, Spain would have 115,473 (95% CI: 114,809--116,140) patients with T2D and 130,316 (95% CI: 129,610--131,025) without T2D who would meet the diagnostic criteria of HF with EF ≤ 40%, NYHA functional class II--IV, and GFR ≥ 30 mL/min/1.73 m².

[Figure 1](#jcm-09-02089-f001){ref-type="fig"} summarizes the sequence of patient selection by the prevalence of patient characteristics or comorbidities analysed, as well as the estimated number of patients with and without each characteristic in Spain.

4. Discussion {#sec4-jcm-09-02089}
=============

4.1. Main Findings {#sec4dot1-jcm-09-02089}
------------------

Among all Spanish patients with HF, the estimated prevalence of patients older than 44 years with reduced EF, NYHA functional class II--IV, and with normal or moderate kidney function (≥30 mL/min/1.73 m²) was about 41.3%. Since the population was selected to meet the clinical characteristics of participants in the DAPA-HF trial, it is conceivable that these patients might also benefit from the positive cardiovascular effects attributed to dapagliflozin, in addition to its glucose-lowering benefits. This new therapeutic indication would benefit the defined HF patient population, with and without T2D, as shown in the DAPA-HF clinical trial \[[@B22-jcm-09-02089]\]. Regardless of the presence of T2D and the risk of worsening HF, death from cardiovascular causes and hospitalizations for HF were significantly less frequent among DAPA-HF participants who received dapagliflozin, compared to those who received a placebo. In the DAPA-HF study, dapagliflozin represents the first in a new class of drug for HF with reduced EF. The DAPA-HF study results introduce the opportunity to further study the potential cardiovascular benefits of SGLT2 inhibitors. Prior studies with empagliflozin \[[@B34-jcm-09-02089]\] and canagliflozin \[[@B35-jcm-09-02089]\] showed a reduction in the relative risk of HF hospitalization in T2D patients, suggesting that the observed benefit is not restricted to a particular drug, but is rather a class effect. The Canagliflozin Cardiovascular Assessment Study (CANVAS) showed that canagliflozin reduced the overall risk of HF events in patients with T2D and high cardiovascular risk. No clear difference in effects on HF with reduced versus preserved events was noted \[[@B36-jcm-09-02089]\]. In addition, the Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) study with dapagliflozin included a reanalysis of retrospectively-obtained EF. The clinical benefit of dapagliflozin was found to be strong in reduced EF in the subset of patient with available EF. In patients with HF without reduced EF, there was only a reduction of hospitalizations, but not in total or cardiovascular mortality \[[@B37-jcm-09-02089]\]. The former was confirmed in the DAPA-HF study. The dapagliflozin effect on mortality in HF-preserved EF patients remains to be conclusively answered

4.2. Reliability of Prevalence Estimates {#sec4dot2-jcm-09-02089}
----------------------------------------

Based on updated demographic information and a comprehensive literature review to obtain reliable prevalence data, we selected the most recent population-based cross-sectional study, in which Farré et al. analysed data from 88,000 individuals representative of the population of Catalonia, with an estimated a 2.7% HF prevalence in people older than 44 years \[[@B14-jcm-09-02089]\]. Due to slight regional differences in age group population distribution, our estimations yielded 2.6% prevalence when applied to all of Spain. The estimations obtained by Farré et al. are also close to European and North American figures, and are more recent than the larger prevalence estimates reported in the meta-analysis by Hernáez et al. \[[@B24-jcm-09-02089]\] and the 2008 Heart Failure Prevalence Study in Spain (PRICE) by Anguita et al. \[[@B15-jcm-09-02089]\].

Given the diversity of hospital departments and primary care settings participating in the published studies, our estimated prevalence of HF patients with reduced EF and NYHA functional class II--IV (52.4% and 84.0%, respectively) reflects the mean values of the main published Spanish registries \[[@B6-jcm-09-02089],[@B7-jcm-09-02089],[@B27-jcm-09-02089],[@B28-jcm-09-02089],[@B29-jcm-09-02089]\]. The obtained prevalence values are in good agreement with the most recent European publications \[[@B5-jcm-09-02089],[@B38-jcm-09-02089]\] in the Southern Europe population. Spanish cardiology departments were well-represented in these European studies, carried out in the context of the ESC Heart Failure Long-Term Registry, which had indicated that the prevalence of reduced EF in patients with chronic HF predominantly admitted to cardiology departments would be around 60%. This is slightly higher than our study's estimate, which was based on HF data from cardiology units, internal medicine, and primary care settings. The Linx Registry, one of the most recent HF studies in Spain, also had a large sample of patients and was carried out in cardiology departments in Catalonia. In that registry, de Frutos et al. \[[@B39-jcm-09-02089]\] estimated that the prevalence of NYHA functional class II--IV in patients with HF and EF ≤ 40% was 85.5%, remarkably close to the estimate obtained in the present study.

We used the 6.1% prevalence of GFR \< 30 mL/min/1.73 m² among chronic HF patients, reported by Crespo-Leiro et al. \[[@B23-jcm-09-02089]\], based on data from 28 Spanish hospitals included in the ESC Heart Failure Long-Term Registry. This is the most recent publication with HF data from Spain, includes the largest series of Spanish patients, and is the only study to provide GFR data generalizable to the HF population. The 6.1% prevalence is among the lowest published in recent decades in Spain, although it is close to the REDINSCOR registry prevalence of 5.5% in HF units within cardiology departments ([Tables S1 and S2](#app1-jcm-09-02089){ref-type="app"}).

4.3. Potential Translational Perspective {#sec4dot3-jcm-09-02089}
----------------------------------------

The results of the DAPA-HF study demonstrated that the primary composite outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio = 0.74; 95% CI: 0.65--0.85; *p* \< 0.001). The largest number of events of worsening HF was hospitalizations. Of the patients receiving dapagliflozin, 231 (9.7%) were hospitalized for HF, compared with 318 patients (13.4%) receiving the placebo (hazard ratio = 0.70; 95% CI: 0.59--0.83). Death from cardiovascular causes occurred in 227 patients (9.6%) who received dapagliflozin, and in 273 (11.5%) who received the placebo (hazard ratio = 0.82; 95% CI: 0.69 to 0.98) \[[@B22-jcm-09-02089]\]. Under the placebo group incidence assumptions, among all 245,789 patients of the estimated Spanish target population, the primary outcome would occur in 52,107 patients, 32,936 patients would be hospitalized for HF, and 28,266 patients would die from cardiovascular causes. With dapagliflozin therapy, the expected annual reduction would consist of 5996 hospitalized patients for HF and 3079 deaths from cardiovascular causes.

4.4. Strengths and Limitations {#sec4dot4-jcm-09-02089}
------------------------------

The main strength of this study is that it combines the estimates from recently published HF prevalence data, enriched by a specific analysis of the REDINSCOR registry database to estimate HF with reduced EF, NYHA functional class II--IV, and GFR ≥ 30 mL/min/1.73 m², with and without T2D prevalence in the Spanish population. However, we decided not to use the estimates based on REDINSCOR database, because the REDINSCOR registry could be biased toward the profile of patients admitted to HF units in cardiology departments, which could depart from the general HF patient population characteristics. All patients included in the REDINSCOR registry had a NYHA class \>I, and the mean estimate of patients with reduced EF was 73%, considerably different from the average of the main Spanish registries that we summarize in [Table 3](#jcm-09-02089-t003){ref-type="table"}. A sensitivity analysis with REDINSCOR patient characteristics is presented in [Table S3](#app1-jcm-09-02089){ref-type="app"}, showing rather higher figures than its corresponding [Table 6](#jcm-09-02089-t006){ref-type="table"} results.

The study also has several limitations. First, we did not take into account the N-terminal pro B-type natriuretic peptide (NT-proBNP) eligibility criteria prevalence in our estimates, due to the absence of prevalence information in the literature and to the probably small reduction in the number of eligibility patients. Second, among the Spanish studies summarized in [Table 3](#jcm-09-02089-t003){ref-type="table"}, the definition of reduced EF varied from EF ≤ 40% to EF ≤ 50%. Furthermore, the GALICAP and EPISERVE studies did not differentiate between chronic and acute HF. Third, we had to assume that the prevalence of NYHA functional class II--IV was the same for reduced, mid-range, and preserved EF, owing to the absence of stratified information in the literature. Likewise, we had to assume that the prevalence of GFR ≥ 30 mL/min/1.73 m² was the same for each type of EF and NYHA functional class, and for all age groups considered in our study. Fourth, the prevalence of diabetic and non-diabetic patients in the REDINSCOR registry could be biased toward the profile of patients admitted to HF units in cardiology departments. Finally, our study does not report prevalence by sex, as the published studies did not provide this stratified information. We firmly support stratification by sex in all future studies, in order to identify the best treatment guidelines to apply in the whole population.

5. Conclusions {#sec5-jcm-09-02089}
==============

In this population analysis, we estimated that approximately 245,789 Spanish patients would meet the inclusion criteria of the DAPA-HF: EF ≤ 40%, NYHA functional class II--IV, and GFR ≥ 30 mL/min/1.73 m², as well as 115,473 with T2D. The magnitude of this population highlights the need to introduce effective and safe new drugs to reduce morbidity and mortality in these patients.
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The following are available online at <https://www.mdpi.com/2077-0383/9/7/2089/s1>, Table S1: Number of patients with the four selection criteria of the DAPA-HF study in the REDINSCOR cohort in Spain. Table S2: Average prevalence of the four main selection criteria of the DAPA-HF study in the REDINSCOR cohort in Spain. Table S3: Total number of patients with heart failure, ejection fraction ≤ 40%, New York Heart Association functional class II--IV, and glomerular filtration rate ≥ 30 mL/min/1.73 m² in Spain and its autonomous communities, according to prevalence data from the REDINSCOR registry (Tables S1 and S2).
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![Flow chart of the Spanish population older than 44 years with heart failure (HF), ejection fraction (EF) ≤ 40%, New York Heart Association (NYHA) functional class II--IV, glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m², and type 2 diabetes mellitus (T2D), according to the estimation specified in the Methods section.](jcm-09-02089-g001){#jcm-09-02089-f001}

jcm-09-02089-t001_Table 1

###### 

Summary of inclusion and exclusion criteria of the DAPA-HF study \[[@B25-jcm-09-02089]\].

  -----------------------------------------------------------------------------------------------------------------------------------------
  **Inclusion Criteria**

  \(1\) Provision of signed informed consent prior to any study specific procedures

  \(2\) Men or women, aged ≥18 years at the time of consent

  \(3\) Diagnosis of HF with left ventricular EF ≤ 40%, which has been present for at least 12 months prior to enrolment

  \(4\) Diagnosis of symptomatic HF (NYHA functional class II--IV), within the previous 2 months

  \(5\) Optimally treated with pharmacological and/or device therapy for HF

  \(6\) NT-proBNP ≥ 600 pg/mL (or if hospitalised for HF within the previous 12 months, NT-proBNP ≥ 400 pg/mL) at enrolment.\
  Patients with atrial fibrillation or atrial flutter must have a level ≥900 pg/mL, irrespective of history of HF hospitalization

  **Exclusion Criteria**

  \(1\) Treatment with SGLT2 inhibitors within 8 weeks prior to enrolment, or previous intolerance of an SGLT2 inhibitor

  \(2\) Diagnosis of type 1 diabetes mellitus

  \(3\) Symptomatic hypotension or systolic blood pressure \<95 mmHg

  \(4\) Recent worsening HF or other cardiovascular events or procedures

  \(5\) Severe (GFR \< 30 mL/min/1.73m² by CKD-EPI equation), unstable, or rapidly progressing renal disease at the time of randomization

  \(6\) Other conditions likely to prevent patient participation in the trial or greatly limit life expectancy
  -----------------------------------------------------------------------------------------------------------------------------------------

DAPA-HF: Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; HF: heart failure; EF: ejection fraction; NYHA: New York Heart Association; NT-proBNP: N-terminal proB-type natriuretic peptide; GFR: glomerular filtration rate; CKD-EPI: Chronic Kidney Disease-Epidemiology Collaboration; SGLT2: sodium-glucose cotransporter-2.

jcm-09-02089-t002_Table 2

###### 

Summary of the heart failure prevalence by age group in population studies in Spain and Europe.

                                            Year of Publication   Country/Region   Study Population   Age, Years (SD)   Women,%   Age Group Prevalence, By Years                                                 
  ----------------------------------------- --------------------- ---------------- ------------------ ----------------- --------- -------------------------------- --------- -------- -------- -------- -------- -------
  Farré et al. \[[@B14-jcm-09-02089]\]      2017                  Catalonia        88,195             77 (12)           55.0%     2.70%                            0.30%     0.90%    2.50%    8.80%             
  Anguita et al. \[[@B15-jcm-09-02089]\]    2008                  Spain            1776               64 (12)           55.9%     6.80%                            1.30%     5.50%    8.00%    16.1%             
                                                                                                                                                                   40--49    50--59   60--69   70--79   ≥80      
  Cortina et al. \[[@B16-jcm-09-02089]\]    2001                  Asturias         391                60 (13)           53.6%     5.00%                            \<1.00%   2.00%    5.00%    13.0%    18.0%    
                                                                                                                                                                   0--49     50--59   60--69   70--79   80--89   ≥90
  Ohlmeier et al. \[[@B17-jcm-09-02089]\]   2015                  Germany          6,284,194          39 (21)           48.2%     1.70%                            0.10%     1.28%    3.88%    10.8%    25.9%    45.7%
                                                                                                                                                                   19--54    55--64   65--74   75--84   85--99   
  Parén et al. \[[@B18-jcm-09-02089]\]      2014                  Sweden           144,925            \-                48.9%     1.99%                            0.13%     1.06%    3.20%    9.23%    20.4%    
                                                                                                                                                                   45--64    65--74   ≥75                        
  Murphy et al. \[[@B31-jcm-09-02089]\]     2004                  Scotland         307,741            \-                50.6%     0.71%                            0.38%     2.30%    6.53%                      
                                                                                                                                                                             55--64   65--74   75--84   ≥85      
  Bleumink et al. \[[@B32-jcm-09-02089]\]   2004                  Rotterdam        7983               70 (10)           61.0%     6.70%                            \-        0.90%    4.00%    9.70%    17.4%    
                                                                                                                                                                   25--49    50--59   60--69   70--79   ≥80      
  Ceia et al. \[[@B33-jcm-09-02089]\]       2002                  Portugal         5434               68 (15)           62.7%     4.36%                            1.36%     2.93%    7.63%    12.7%    16.1%    

SD: standard deviation.

jcm-09-02089-t003_Table 3

###### 

Studies of patients with heart failure in Spain.

  Study                               Year of Publication   Study Population   Age, Years (SD)   Women, %   Type of Heart Failure   Geographical Area        Specialty                                         Reduced EF   NYHA Class II--IV
  ----------------------------------- --------------------- ------------------ ----------------- ---------- ----------------------- ------------------------ ------------------------------------------------- ------------ -------------------
  RICA \[[@B27-jcm-09-02089]\]        2017                  1396               79 (8)            54.0%      chronic                 Spain                    Internal medicine                                 39.5%        80.2%
  REDINSCOR \[[@B27-jcm-09-02089]\]   2017                  2150               70 (10)           31.0%      chronic                 Spain                    Cardiology                                        79.6%        100% ¹
  BADAPIC \[[@B6-jcm-09-02089]\]      2010                  4720               65 (12)           29.0%      chronic                 Spain                    Cardiology                                        63.4%        100% ¹
  INCA \[[@B7-jcm-09-02089]\]         2009                  2161               71 (11)           44.4%      chronic                 Spain                    Primary care and cardiology                       38.3%        84.0%
  EPISERVE \[[@B28-jcm-09-02089]\]    2008                  2249               72 (10)           45.0%      \-                      Spain, except La Rioja   Primary care, cardiology, and internal medicine   55.0%        90.4%
  GALICAP \[[@B29-jcm-09-02089]\]     2007                  1195               76 (10)           52.1%      \-                      Galicia                  Primary care                                      38.6%        81.5%
  Mean                                                      52.4%              84.0%                                                                                                                                        

¹ Data not included in the calculation of NYHA functional class II--IV average. RICA: National Registry for Heart Failure; REDINSCOR: Spanish Network for Heart Failure; BADAPIC: Database of Patients with Heart Failure; INCA: Heart Failure Study; EPISERVE: Heart Failure in Outpatients; GALICAP: Galician Study of Heart Failure in Primary Care; SD: standard deviation; Reduced EF: ejection fraction less than 40--50%; NYHA: New York Heart Association.

jcm-09-02089-t004_Table 4

###### 

Total population in Spain according to 2019 data from the National Statistics Institute \[[@B26-jcm-09-02089]\], and the number of patients with heart failure in Spain and its autonomous communities, according to prevalence data published by Farré et al. \[[@B14-jcm-09-02089]\].

                               General Population (by Age Group)   Heart Failure Prevalence (by Age Group)                                                                                                                                                
  ---------------------------- ----------------------------------- ----------------------------------------- ---------------------- ---------------------- ---------------------- ------------------ ---------------- ---------------- ------------------ ------------------
  Autonomous Communities                                                                                                                                                                             0.30%            0.90%            2.50%              8.80%
  Andalucía                    3,895,025                           1,341,487                                 1,093,149              770,187                690,202                93,855             4024             9838             19,255             60,738
  Aragón                       674,882                             207,355                                   180,224                136,185                151,118                18,947             622              1622             3405               13,298
  Principado de Asturias       589,263                             164,027                                   161,384                131,949                131,903                16,851             492              1452             3299               11,607
  Illes Balears                529,589                             194,110                                   145,007                103,545                86,927                 12,126             582              1305             2589               7650
  Canarias                     1,048,012                           390,823                                   293,621                199,438                164,130                23,244             1172             2643             4986               14,443
  Cantabria                    307,255                             93,358                                    85,403                 65,351                 63,143                 8239               280              769              1634               5557
  Castilla y León              1,347,618                           376,632                                   361,698                275,863                333,425                40,623             1130             3255             6897               29,341
  Castilla-La Mancha           974,147                             320,338                                   265,833                180,457                207,519                26,127             961              2392             4511               18,262
  Catalunya                    3,593,591                           1,188,206                                 946,935                738,057                720,393                93,933             3565             8522             18,451             63,395
  Comunitat Valenciana         2,437,743                           799,940                                   658,274                508,440                471,089                62,491             2400             5924             12,711             41,456
  Extremadura                  537,686                             166,131                                   151,011                104,505                116,039                14,682             498              1359             2613               10,211
  Galicia                      1,484,698                           424,418                                   377,370                322,257                360,653                44,463             1273             3396             8056               31,737
  Comunidad de Madrid          3,099,482                           1,074,013                                 826,152                609,975                589,342                77,769             3222             7435             15,249             51,862
  Región de Murcia             648,115                             234,820                                   176,760                123,046                113,489                15,358             704              1591             3076               9987
  Comunidad Foral de Navarra   317,203                             102,519                                   84,911                 64,649                 65,124                 8419               308              764              1616               5731
  País Vasco                   1,156,253                           347,445                                   312,977                247,706                248,125                31,887             1042             2817             6193               21,835
  La Rioja                     158,846                             49,143                                    43,080                 32,058                 34,565                 4378               147              388              801                3042
  Ciudad Autónoma de Ceuta     32,632                              12,059                                    10,246                 5676                   4651                   680                36               92               142                409
  Ciudad Autónoma de Melilla   30,008                              11,057                                    9737                   5077                   4137                   612                33               88               127                364
  All Communities              22,862,048                          7,497,881                                 6,183,772              4,624,421              4,555,974              594,684            22,494           55,654           115,611            400,926
  95% CI                       22,852,679--22,871,420              7,492,516--7,503,249                      6,178,900--6,188,647   4,620,208--4,628,637   4,551,792--4,560,158   593,175--596,196   22,202--22,789   55,194--56,117   114,947--116,278   399,687--402,168

CI: Confidence interval.

jcm-09-02089-t005_Table 5

###### 

Total number of patients in Spain and its autonomous communities with heart failure and ejection fraction ≤ 40%, as well as the number of heart failure patients with average ejection fraction ≤ 40% and in New York Heart Association functional class II--IV (based on data summarized in [Table 3](#jcm-09-02089-t003){ref-type="table"}).

                               Heart Failure + Ejection Fraction ≤ 40% (by Age Group)   Heart Failure + Ejection Fraction ≤ 40% + NYHA Class II--IV (by Age Group)                                                                                                                             
  ---------------------------- -------------------------------------------------------- ---------------------------------------------------------------------------- ---------------- ----------------- ------------------ ------------------ -------------- ---------------- ---------------- ------------------
  Autonomous Communities                                                                52.4%                                                                        52.4%            52.4%             52.4%                                 84.0%          84.0%            84.0%            84.0%
  Andalucía                    49,180                                                   2109                                                                         5155             10,089            31,827             41,311             1771           4330             8475             26,734
  Aragón                       9928                                                     326                                                                          850              1784              6968               8340               274            714              1499             5853
  Principado de Asturias       8830                                                     258                                                                          761              1729              6082               7417               217            639              1452             5109
  Illes Balears                6354                                                     305                                                                          684              1356              4008               5337               256            574              1139             3367
  Canarias                     12,180                                                   614                                                                          1385             2613              7568               10,231             516            1163             2195             6357
  Cantabria                    4317                                                     147                                                                          403              856               2912               3627               123            338              719              2446
  Castilla y León              21,287                                                   592                                                                          1706             3614              15,375             17,881             497            1433             3036             12,915
  Castilla-La Mancha           13,690                                                   504                                                                          1254             2364              9569               11,500             423            1053             1986             8038
  Catalunya                    49,221                                                   1868                                                                         4466             9669              33,219             41,346             1569           3751             8122             27,904
  Comunitat Valenciana         32,745                                                   1258                                                                         3104             6661              21,723             27,506             1056           2608             5595             18,247
  Extremadura                  7693                                                     261                                                                          712              1369              5351               6462               219            598              1150             4495
  Galicia                      23,299                                                   667                                                                          1780             4222              16,630             19,571             560            1495             3546             13,970
  Comunidad de Madrid          40,751                                                   1688                                                                         3896             7991              27,176             34,231             1418           3273             6712             22,828
  Región de Murcia             8048                                                     369                                                                          834              1612              5233               6760               310            700              1354             4396
  Comunidad Foral de Navarra   4411                                                     161                                                                          400              847               3003               3706               135            336              711              2523
  País Vasco                   16,709                                                   546                                                                          1476             3245              11,442             14,035             459            1240             2726             9611
  La Rioja                     2294                                                     77                                                                           203              420               1594               1927               65             171              353              1339
  Ciudad Autónoma de Ceuta     356                                                      19                                                                           48               74                214                299                16             41               62               180
  Ciudad Autónoma de Melilla   321                                                      17                                                                           46               67                191                269                15             39               56               160
  All Communities              311,614                                                  11,787                                                                       29,163           60,580            210,085            261,756            9901           24,497           50,887           176,471
  95% CI                       310,522--312,709                                         11,576--12,001                                                               28,830--29,499   60,100-- 61,063   209,189--210,984   260,755--262,760   9708--10,097   24,192--24,805   50,447--51,330   175,650--177,295

NYHA: New York Heart Association; CI: Confidence interval.

jcm-09-02089-t006_Table 6

###### 

Total number of patients with heart failure ejection fraction ≤ 40%, New York Heart Association functional class II--IV, and glomerular filtration rate ≥ 30 mL/min/1.73 m² in Spain and its autonomous communities \[[@B23-jcm-09-02089]\].

                               HF + EF ≤ 40% + NYHA Class II--IV + GFR ≥ 30 (by Age Group)                                                    
  ---------------------------- ------------------------------------------------------------- -------------- ---------------- ---------------- ------------------
  Autonomous Communities                                                                     93.9%          93.9%            93.9%            93.9%
  Andalucía                    38,791                                                        1663           4066             7958             25,104
  Aragón                       7831                                                          257            670              1407             5496
  Principado de Asturias       6965                                                          203            600              1363             4797
  Illes Balears                5012                                                          241            539              1070             3162
  Canarias                     9607                                                          485            1092             2061             5970
  Cantabria                    3405                                                          116            318              675              2297
  Castilla y León              16,790                                                        467            1345             2850             12,127
  Castilla-La Mancha           10,798                                                        397            989              1865             7548
  Catalunya                    38,823                                                        1473           3522             7626             26,202
  Comunitat Valenciana         25,828                                                        992            2449             5254             17,134
  Extremadura                  6068                                                          206            562              1080             4220
  Galicia                      18,377                                                        526            1404             3330             13,117
  Comunidad de Madrid          32,143                                                        1332           3073             6303             21,435
  Región de Murcia             6348                                                          291            658              1271             4128
  Comunidad Foral de Navarra   3480                                                          127            316              668              2369
  País Vasco                   13,179                                                        431            1164             2559             9025
  La Rioja                     1810                                                          61             160              331              1257
  Ciudad Autónoma de Ceuta     281                                                           15             38               59               169
  Ciudad Autónoma de Melilla   253                                                           14             36               52               150
  All Communities              245,789                                                       9297           23,002           47,783           165,707
  95% CI                       244,819--246,762                                              9,110--9,487   22,707--23,300   47,357--48,212   164,911--166,506

HF: heart failure; EF: ejection fraction; NYHA: New York Heart Association; GFR: glomerular filtration rate. (mL/min/1.73 m²); CI: Confidence interval.

jcm-09-02089-t007_Table 7

###### 

Total number of patients with heart failure, ejection fraction ≤ 40%, New York Heart Association functional class II--IV, and glomerular filtration rate ≥ 30 mL/min/1.73 m², with or without type 2 diabetes mellitus, in Spain and its autonomous communities, according to prevalence data from the REDINSCOR registry ([Tables S1 and S2](#app1-jcm-09-02089){ref-type="app"}).

                               HF + EF ≤ 40% + NYHA Class II--IV + GFR ≥ 30 + Diabetes (by Age Group)   HF + EF ≤ 40% + NYHA Class II--IV + GFR ≥ 30 (No Diabetes) (by Age Group)                                                                                                                    
  ---------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------------------- ------------ ---------------- ---------------- ------------------ ------------ ---------------- ---------------- ----------------
  Autonomous Communities                                                                                28.7%                                                                       40.7%        49.2%            48.2%                               71.3%        59.3%            50.8%            51.8%
  Andalucía                    18,157                                                                   478                                                                         1654         3914             12,111           20,634             1185         2412             4044             12,993
  Aragón                       3690                                                                     74                                                                          273          692              2652             4141               183          398              715              2845
  Principado de Asturias       3288                                                                     58                                                                          244          671              2314             3677               145          356              693              2483
  Illes Balears                2340                                                                     69                                                                          219          526              1525             2672               172          320              544              1636
  Canarias                     4477                                                                     139                                                                         444          1014             2880             5130               345          648              1047             3090
  Cantabria                    1603                                                                     33                                                                          129          332              1108             1803               82           188              343              1189
  Castilla y León              7934                                                                     134                                                                         547          1402             5851             8856               333          798              1448             6277
  Castilla-La Mancha           5075                                                                     114                                                                         402          917              3641             5724               283          587              947              3906
  Catalunya                    18,248                                                                   423                                                                         1433         3751             12,641           20,576             1050         2090             3875             13,561
  Comunitat Valenciana         12,131                                                                   285                                                                         996          2584             8266             13,697             707          1453             2670             8868
  Extremadura                  2855                                                                     59                                                                          228          531              2036             3213               147          333              549              2184
  Galicia                      8688                                                                     151                                                                         571          1638             6328             9689               375          833              1692             6789
  Comunidad de Madrid          15,074                                                                   383                                                                         1250         3100             10,341           17,069             949          1823             3203             11,094
  Región de Murcia             2968                                                                     84                                                                          267          625              1991             3380               207          390              646              2136
  Comunidad Foral de Navarra   1636                                                                     37                                                                          128          329              1143             1843               91           187              339              1226
  País Vasco                   6210                                                                     124                                                                         473          1259             4,354            6969               307          691              1301             4671
  La Rioja                     852                                                                      18                                                                          65           163              607              957                43           95               168              651
  Ciudad Autónoma de Ceuta     130                                                                      4                                                                           16           29               82               151                11           23               30               88
  Ciudad Autónoma de Melilla   117                                                                      4                                                                           15           26               73               136                10           21               27               78
  All Communities              115,473                                                                  2672                                                                        9355         23,503           79,943           130,316            6625         13,647           24,280           85,764
  95% CI                       114,809--116,140                                                         2573--2774                                                                  9167--9546   23,205--23,804   79,391--80,498   129,610--131,025   6467--6786   13,420--13,877   23,977--24,586   85,192--86,339

HF: heart failure; EF: ejection fraction; NYHA: New York Heart Association; GFR: glomerular filtration rate (mL/min/1.73 m²); CI: Confidence interval.

[^1]: These authors contributed equally to this work.
